Cargando…
IGF1 as a Potential Treatment for Rett Syndrome: Safety Assessment in Six Rett Patients
Rett syndrome (RTT) is a devastating neurodevelopmental disorder that affects one in ten thousand girls and has no cure. The majority of RTT patients display mutations in the gene that codes for the methyl-CpG-binding protein 2 (MeCP2). Clinical observations and neurobiological analysis of mouse mod...
Autores principales: | Pini, Giorgio, Scusa, Maria Flora, Congiu, Laura, Benincasa, Alberto, Morescalchi, Paolina, Bottiglioni, Ilaria, Di Marco, Pietro, Borelli, Paolo, Bonuccelli, Ubaldo, Della-Chiesa, Andrea, Prina-Mello, Adriele, Tropea, Daniela |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Hindawi Publishing Corporation
2012
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3420537/ https://www.ncbi.nlm.nih.gov/pubmed/22934177 http://dx.doi.org/10.1155/2012/679801 |
Ejemplares similares
-
Rett syndrome: a wide clinical and autonomic picture
por: Pini, G., et al.
Publicado: (2016) -
Repeated Insulin-Like Growth Factor 1 Treatment in a Patient with Rett Syndrome: A Single Case Study
por: Pini, Giorgio, et al.
Publicado: (2014) -
Illness Severity, Social and Cognitive Ability, and EEG Analysis of Ten Patients with Rett Syndrome Treated with Mecasermin (Recombinant Human IGF-1)
por: Pini, Giorgio, et al.
Publicado: (2016) -
Functional Network Mapping Reveals State-Dependent Response to IGF1 Treatment in Rett Syndrome
por: Keogh, Conor, et al.
Publicado: (2020) -
Neurophysiology versus clinical genetics in Rett syndrome: A multicenter study
por: Halbach, Nicky, et al.
Publicado: (2016)